journal
https://read.qxmd.com/read/38401552/the-rise-of-syphilis-a-call-to-action-for-dermatologists
#41
LETTER
Hitaishi Mehta, Anuradha Bishnoi, Keshavamurthy Vinay
No abstract text is available yet for this article.
February 21, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38401551/effectiveness-of-pyriproxyfen-pyrethroid-and-chlorfenapyr-pyrethroid-long-lasting-insecticidal-nets-llins-compared-with-pyrethroid-only-llins-for-malaria-control-in-the-third-year-post-distribution-a-secondary-analysis-of-a-cluster-randomised-controlled-trial
#42
JOURNAL ARTICLE
Manfred Accrombessi, Jackie Cook, Edouard Dangbenon, Arthur Sovi, Boulais Yovogan, Landry Assongba, Constantin J Adoha, Bruno Akinro, Cyriaque Affoukou, Germain Gil Padonou, Immo Kleinschmidt, Louisa A Messenger, Mark Rowland, Corine Ngufor, Martin C Akogbeto, Natacha Protopopoff
BACKGROUND: Malaria continues to kill approximately 650 000 people each year. There is evidence that some second-generation insecticide-treated nets, which combine insecticide formulations with different modes of action, are protective against malaria while the nets are new; however, evidence for their impact over 3 years is scarce. In this study, we report the third-year results of a cluster-randomised controlled trial assessing the long-term effectiveness of dual-active ingredient long-lasting insecticidal nets (LLINs)...
February 21, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38395047/global-incidence-and-mortality-of-severe-fungal-disease-author-s-reply
#43
LETTER
David W Denning
No abstract text is available yet for this article.
February 20, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38395046/global-incidence-and-mortality-of-severe-fungal-disease
#44
LETTER
Kevin S Ikuta, Tomislav Meštrović, Mohsen Naghavi
No abstract text is available yet for this article.
February 20, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38387473/access-to-respiratory-syncytial-virus-preventive-tools-for-neonates-and-infants-in-europe
#45
JOURNAL ARTICLE
Caitlin Pley, Beate Kampmann
No abstract text is available yet for this article.
February 19, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38373425/the-role-of-nitags-in-government-decisions-on-vaccine-use-insights-from-the-fifth-global-nitag-network-meeting
#46
LETTER
Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach
No abstract text is available yet for this article.
February 16, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38368892/inside-the-circle
#47
JOURNAL ARTICLE
Jamie Prowse
No abstract text is available yet for this article.
February 15, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38368891/evolution-of-respiratory-syncytial-virus-burden-in-young-children-following-the-covid-19-pandemic-influence-of-concomitant-changes-in-testing-practices
#48
LETTER
Inès Fafi, Zein Assad, Léa Lenglart, Zaba Valtuille, Naïm Ouldali
No abstract text is available yet for this article.
February 15, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38368890/transjugular-intrahepatic-portosystemic-shunt-followed-by-splenectomy-for-complicated-hepatosplenic-schistosomiasis-a-case-report-and-review-of-the-literature
#49
REVIEW
Francesca Tamarozzi, Tamara Ursini, Giacomo Stroffolini, Geraldo Badona Monteiro, Dora Buonfrate, Veronica Andrea Fittipaldo, Simone Conci, Clizia Gasparini, Giancarlo Mansueto, Alfredo Guglielmi, Federico Gobbi
Hepatosplenic schistosomiasis is a complex clinical condition caused by the complications of chronic infection with Schistosoma species that cause intestinal schistosomiasis. Hepatosplenic schistosomiasis derives from the fibrotic reaction stimulated around parasite eggs that are transported by the mesenteric circulation to the liver, causing periportal fibrosis. Portal hypertension and variceal gastrointestinal bleeding are major complications of hepatosplenic schistosomiasis. The clinical management of hepatosplenic schistosomiasis is not standardised and a parameter that could guide clinical decision making has not yet been identified...
February 15, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38368889/evolution-of-respiratory-syncytial-virus-burden-in-young-children-following-the-covid-19-pandemic-influence-of-concomitant-changes-in-testing-practices-author-s-reply
#50
LETTER
https://read.qxmd.com/read/38367636/managing-treatment-failure-in-neisseria-gonorrhoeae-infection-current-guidelines-and-future-directions
#51
REVIEW
Lao-Tzu Allan-Blitz, Helen Fifer, Jeffrey D Klausner
Due to the continued emergence of resistance to extended-spectrum cephalosporin antibiotics, clinicians are increasingly more likely to encounter cases of Neisseria gonorrhoeae treatment failure. The current international treatment guidelines offer few regimens for cases of N gonorrhoeae infection that do not respond to first-line therapy, and there are many complexities that should be considered with such regimens; these include regional variations in resistance to alternative agents, access to different antibiotics, and penetration of those antibiotics within different tissues...
February 14, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38359856/chatgpt-does-not-neglect-a-neglected-disease-if-appropriately-prompted-authors-reply
#52
LETTER
Mathieu Nacher, Ugo Françoise, Antoine Adenis
No abstract text is available yet for this article.
February 12, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38359855/a-novel-dual-targeted-antibacterial-agent-for-helicobacter-pylori
#53
JOURNAL ARTICLE
Jinnan Chen, Hong Lu
No abstract text is available yet for this article.
February 12, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38359854/safety-pharmacokinetics-and-efficacy-of-rifasutenizol-a-novel-dual-targeted-antibacterial-agent-in-healthy-participants-and-patients-in-china-with-helicobacter-pylori-infection-four-randomised-clinical-trials
#54
JOURNAL ARTICLE
Xiaojiao Li, Yusi Liu, Meng Wang, Lei Gao, Jingrui Liu, Hong Zhang, Min Wu, Hong Chen, Jinfeng Lou, Jing Wang, Jing Chen, Guozhu Geng, Zhenkun Ma, Yanhua Ding
BACKGROUND: Due to the rapid development of antimicrobial resistance, the efficacy of most Helicobacter pylori eradication therapies have progressively decreased to an unacceptable level. Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action currently under clinical development for the treatment of microaerophilic and anaerobic bacterial infections. We aimed to evaluate the safety, pharmacokinetics, and efficacy of rifasutenizol in healthy Chinese participants and patients with H pylori...
February 12, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38346436/global-guideline-for-the-diagnosis-and-management-of-cryptococcosis-an-initiative-of-the-ecmm-and-isham-in-cooperation-with-the-asm
#55
REVIEW
Christina C Chang, Thomas S Harrison, Tihana A Bicanic, Methee Chayakulkeeree, Tania C Sorrell, Adilia Warris, Ferry Hagen, Andrej Spec, Rita Oladele, Nelesh P Govender, Sharon C Chen, Christopher H Mody, Andreas H Groll, Yee-Chun Chen, Michail S Lionakis, Alexandre Alanio, Elizabeth Castañeda, Jairo Lizarazo, José E Vidal, Takahiro Takazono, Martin Hoenigl, Jan-Willem Alffenaar, Jean-Pierre Gangneux, Rajeev Soman, Li-Ping Zhu, Alexandro Bonifaz, Joseph N Jarvis, Jeremy N Day, Nikolai Klimko, Jon Salmanton-García, Grégory Jouvion, David B Meya, David Lawrence, Sebastian Rahn, Felix Bongomin, Brendan J McMullan, Rosanne Sprute, Tinashe K Nyazika, Justin Beardsley, Fabianne Carlesse, Christopher H Heath, Olusola O Ayanlowo, Olga M Mashedi, Flavio Queiroz-Telles Filho, Mina C Hosseinipour, Atul K Patel, Elvis Temfack, Nina Singh, Oliver A Cornely, David R Boulware, Olivier Lortholary, Peter G Pappas, John R Perfect
Cryptococcosis is a major worldwide disseminated invasive fungal infection. Cryptococcosis, particularly in its most lethal manifestation of cryptococcal meningitis, accounts for substantial mortality and morbidity. The breadth of the clinical cryptococcosis syndromes, the different patient types at-risk and affected, and the vastly disparate resource settings where clinicians practice pose a complex array of challenges. Expert contributors from diverse regions of the world have collated data, reviewed the evidence, and provided insightful guideline recommendations for health practitioners across the globe...
February 9, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38342108/the-deadly-potential-of-chikungunya-virus
#56
JOURNAL ARTICLE
Henrik Salje, Oscar Cortés Azuero
No abstract text is available yet for this article.
February 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38342107/the-public-health-impact-and-cost-effectiveness-of-the-r21-matrix-m-malaria-vaccine-a-mathematical-modelling-study
#57
JOURNAL ARTICLE
Nora Schmit, Hillary M Topazian, H Magloire Natama, Duncan Bellamy, Ousmane Traoré, M Athanase Somé, Toussaint Rouamba, Marc Christian Tahita, Massa Dit Achille Bonko, Aboubakary Sourabié, Hermann Sorgho, Lisa Stockdale, Samuel Provstgaard-Morys, Jeremy Aboagye, Danielle Woods, Katerina Rapi, Mehreen S Datoo, Fernando Ramos Lopez, Giovanni D Charles, Kelly McCain, Jean-Bosco Ouedraogo, Mainga Hamaluba, Ally Olotu, Alassane Dicko, Halidou Tinto, Adrian V S Hill, Katie J Ewer, Azra C Ghani, Peter Winskill
BACKGROUND: The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and cost-effectiveness of vaccine introduction across sub-Saharan Africa. METHODS: We fitted a semi-mechanistic model of the relationship between anti-circumsporozoite protein antibody titres and vaccine efficacy to data from 3 years of follow-up in the phase 2b trial of R21/Matrix-M in Nanoro, Burkina Faso...
February 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38342106/risk-of-death-following-chikungunya-virus-disease-in-the-100-million-brazilian-cohort-2015-18-a-matched-cohort-study-and-self-controlled-case-series
#58
JOURNAL ARTICLE
Thiago Cerqueira-Silva, Julia M Pescarini, Luciana L Cardim, Clémence Leyrat, Heather Whitaker, Carlos Alexandre Antunes de Brito, Elizabeth B Brickley, Manoel Barral-Netto, Maurício L Barreto, Maria G Teixeira, Viviane S Boaventura, Enny S Paixão
BACKGROUND: Chikungunya virus outbreaks have been associated with excess deaths at the ecological level. Previous studies have assessed the risk factors for severe versus mild chikungunya virus disease. However, the risk of death following chikungunya virus disease compared with the risk of death in individuals without the disease remains unexplored. We aimed to investigate the risk of death in the 2 years following chikungunya virus disease. METHODS: We used a population-based cohort study and a self-controlled case series to estimate mortality risks associated with chikungunya virus disease between Jan 1, 2015, and Dec 31, 2018, in Brazil...
February 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38342105/chikungunya-seroprevalence-force-of-infection-and-prevalence-of-chronic-disability-after-infection-in-endemic-and-epidemic-settings-a-systematic-review-meta-analysis-and-modelling-study
#59
JOURNAL ARTICLE
Hyolim Kang, Megan Auzenbergs, Hannah Clapham, Clara Maure, Jong-Hoon Kim, Henrik Salje, Christopher G Taylor, Ahyoung Lim, Andrew Clark, W John Edmunds, Sushant Sahastrabuddhe, Oliver J Brady, Kaja Abbas
BACKGROUND: Chikungunya is an arboviral disease transmitted by Aedes aegypti and Aedes albopictus mosquitoes with a growing global burden linked to climate change and globalisation. We aimed to estimate chikungunya seroprevalence, force of infection (FOI), and prevalence of related chronic disability and hospital admissions in endemic and epidemic settings. METHODS: In this systematic review, meta-analysis, and modelling study, we searched PubMed, Ovid, and Web of Science for articles published from database inception until Sept 26, 2022, for prospective and retrospective cross-sectional studies that addressed serological chikungunya virus infection in any geographical region, age group, and population subgroup and for longitudinal prospective and retrospective cohort studies with data on chronic chikungunya or hospital admissions in people with chikungunya...
February 8, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38342104/determining-force-of-infection-for-chikungunya-to-support-vaccine-policy-development
#60
JOURNAL ARTICLE
Annika Beate Wilder-Smith, Annelies Wilder-Smith
No abstract text is available yet for this article.
February 8, 2024: Lancet Infectious Diseases
journal
journal
20187
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.